Nijmegen, Netherlands, 29-06-2024 – Avivia, is pleased to announce the successful completion of a management buyout (MBO). This strategic move marks a significant milestone for Avivia, positioning it for future growth and continued success.
The MBO was led by the Directors Dennie van den Heuvel and Menno Wiltink, who have demonstrated unwavering commitment and dedication to the company’s vision and values. This transaction underscores the management team’s confidence in Avivia’s long-term potential and their commitment to driving the company forward.
Key Highlights of the Buyout:
Strategic focus: The management buyout allows Avivia to focus on the service business , and ensure continued to prioritization of customer satisfaction operational excellence, and innovation.
Leadership Transition: The buyout was led by Directors Dennie van den Heuvel and Menno Wiltink, who have consistently demonstrated commitment to Avivia’s vision and values. Their leadership will be further strengthened with the addition of Lee Ayres as the new Managing Director. Ayres brings a wealth of experience in business development and marketing, promising to enhance the company’s leadership team.
Future Growth: The buyout provides the company with the flexibility and resources to invest in new opportunities, expand its market presence, and enhance product offerings.
New Managing Director Lee Ayres expressed enthusiasm about the buyout, stating, “This is an exciting new chapter for Avivia. Our team is fully committed to leveraging this opportunity to accelerate our growth and deliver even greater value to our customers and stakeholders. We believe in the strength of our offering, our ability to deliver complex projects, and the dedication of our employees. The team is ready to embark on this next phase of our journey together. together.”
About Avivia
Avivia is a pharmaceutical R&D service company, specializing in innovative pharmaceutical formulation development and characterization. Avivia’s mission is to support our customers in creating new and improved medicines that benefit patients. We use our unique combination of expertise and experience in complex formulation development and analysis to seamlessly guide our customers in bridging the gap between development of the Active Pharmaceutical Ingredient (API) and manufacturing of the final pharmaceutical product. Avivia also provides hands-on support in fields such as analysis, characterization, dissolution testing, life cycle management and generation/protection of intellectual property for both generic and new drug products.
We have a broad and diverse customer base, from big pharma and generic drug companies to excipient manufacturers and Universities.
